Home > Compound List > Product Information
Methantheline_Molecular_structure_CAS_5818-17-7)
Click picture or here to close

Methantheline

Catalog No. DB00940 Name DrugBank
CAS Number 5818-17-7 Website http://www.ualberta.ca/
M. F. C21H26BrNO3 Telephone (780) 492-3111
M. W. 420.34004 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 816

SYNONYMS

IUPAC name
diethyl(methyl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium bromide
IUPAC Traditional name
methantheline bromide
Brand Name
Resobantin
Vagamin
Banthine
Frenogastrico
Asabaine
Dixamone Bromide
Doladene
Gastrin I
Gastrosedan
Metantyl
Metaxan
Methelina
Avagal
Banthin
Gastrin-1 Human
Gastron
Mantheline
Methanide
Ulcine
Ulcudexter
Vagantin
Xanteline
Synonyms
Methanthelinum
Methanthine Bromide
Methantheline Bromide
Methanthelinium
Methanthelinium Bromide
MTB 51
Banthine Bromide

DATABASE IDS

PubChem SID 46505807
CAS Number 5818-17-7
PubChem CID 4097

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problems (irritable bowel syndrome), pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, or urinary problems (reflex neurogenic bladder in children).
Indication For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.
Pharmacology Methantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline inhibits muscarinic actions at postganglionic parasympathetic neuroeffector sites.
Toxicity Symptoms of overdose: blurred vision (continuing) or changes in near vision, clumsiness or unsteadiness, confusion, convulsions, difficulty in breathing, muscle weakness (severe), or tiredness (severe), dizziness, drowsiness (severe), dryness of mouth, nose, or throat (severe), fast heartbeat, fever, hallucinations, slurred speech, unusual excitement, nervousness, restlessness, or irritability, unusual warmth, dryness, and flushing of skin.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, by enzymatic hydrolysis.
Absorption Rapidly absorbed.

REFERENCES